AU Patent

AU2013229922B2 — 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors

Assigned to Kyntra Bio Inc · Expires 2017-09-28 · 9y expired

What this patent protects

The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as…

USPTO Abstract

The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013229922B2
Jurisdiction
AU
Classification
—
Expires
2017-09-28
Drug substance claim
No
Drug product claim
No
Assignee
Kyntra Bio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.